Mesoblast Limited
MESO

NASDAQ > Biotechnology
DCF:$0.75  |   P/E: -
$1.23(8.37%)
Change
Rating:
Price: $14.63 USD
Market Cap: $1.81B

...Loading MESO Peers...





Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

    73 Employees

    CEO : Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)

    Address : 55 Collins Street, Melbourne,VIC, AU, - 3000,

Key ExcutivesDesignation
Mr. Andrew Chaponnel B.Com.Interim Chief Finance Officer
Dr. Paul J. Simmons BSc, Ph.D.Scientific Advisor to the Chief Executive Officer
Ms. Niva Sivakumar B.Com., L.L.B.Joint Company Secretary
Dr. Fiona See Ph.D.Senior Vice President & Head of Translational Research
Mr. Paul Hughes BPHARMJoint Company Secretary
Mr. Peter T. Howard B.Sc., L.L.B., LLB (Hons)General Counsel & Corporate Executive
Ms. Geraldine Storton B.Sc., M.B.A., MMSHead of Regulatory Affairs & Quality Management
Mr. Justin Horst B.S.Head of Manufacturing
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)Founder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board & Executive Director
Dr. Eric A. Rose M.D.Chief Medical Officer & Executive Director